by Romain Magnez | Sep 11, 2019 | News
Vaxinano : des vaccins sans adjuvant et sans aiguille Vaxinano développe des vaccins sûrs, plus stables et plus efficaces, sans adjuvant et sans aiguille. Leur technologie brevetée est centrée sur l’utilisation de nanoparticules biodisponibles et...
by Romain Magnez | Sep 11, 2018 | News
Vaxinano peaufine son vaccin sans adjuvant administré par voie nasale Développant des vaccins sans adjuvant, administrés par voie nasale et 100 % bioéliminables, Vaxinano vient de finaliser un tour de table à 1,2 million d’euros. Avec les 400.000 euros levés cet...
by Romain Magnez | Sep 9, 2018 | Publications
New publication on Non-human Primate toxoplasmosis vaccination Title : Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections. Bernasconi et al....
by Romain Magnez | Sep 11, 2017 | News
Founded in July 2016 within the Eurasanté bio-incubator in Lille, Vaxinano is developing the first vaccine against toxoplasmosis. It is based on “nanoparticles composed of cornstarch and lipids that are non-toxic and eliminated by the body within 48 hours,” explains...
by Romain Magnez | Jul 10, 2016 | Publications
New publication has been released on congenital toxoplasmosis vaccine Title : Synthetic parasites: a successful mucosal nanoparticle vaccine against Toxoplasma congenital infection in mice. Ducournau et al. 2016. Future Microbiology Le et al. 2020. International...
